Atopic Dermatitis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Atopic Dermatitis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month12 studies across 7 companies, in the next 180 days.
August 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GENB | Generate Biomedicines | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult ParticipantsNCT06920693Composite Outcome: To assess the safety and tolerability of single doses of GB-7624 administered subcutaneously (SC) in healthy volunteers. | Phase 1 | Active, not recruiting | 2026-08-30 | in 10 d | 2025-12-05 |
| ABBV | AbbVie | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabNCT06389136Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) | Phase 3 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-06 |
| ACRS | Aclaris Therapeutics, Inc. | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706Percent Change in Eczema Area and Severity Index (EASI) | Phase 2 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-03-25 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in SpainNCT06415175observationalDemographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age | — | Active, not recruiting | 2026-09-30 | in 41 d | 2026-02-25 |
October 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)NCT02612454Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit | Phase 3 | Active, not recruiting | 2026-10-07 | in 48 d | 2026-05-29 |
| PFE | Pfizer | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisNCT05995964The number of participants achieving ≥75% improvement in EAS175 from baseline at week16. | Phase 2 | Recruiting | 2026-10-19 | in 60 d | 2026-05-04 |
| ABBV | AbbVie | A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic DermatitisNCT05081557observationalUpadacitinib (UPA) Utilization Patterns | — | Active, not recruiting | Oct 2026 | ≤ 72 d | 2025-08-14 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | A Study Evaluating APG777 in Atopic DermatitisNCT06395948Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI) | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-22 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisNCT07027527Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-06-08 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)NCT03936335observationalPrevalence of MCMs | — | Recruiting | 2027-01-21 | in 154 d | 2025-08-03 |
| ABBV | AbbVie | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisNCT06701331Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75 | Phase 3 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2026-02-23 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.NCT06899204observationalPercentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date | — | Recruiting | 2027-02-15 | in 179 d | 2026-08-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Atopic Dermatitis
most recently updated first322 studies match. Showing the first 100 of 322 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | $24.7B | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisNCT06832618VC Period: Binary response status of Eczema Area and Severity Index 75 (EASI75) | Phase 3 | Active, not recruiting | Drug: Ruxolitinib, Vehicle Cream | Atopic Dermatitis | 159 | 2025-06-17 | 2026-08-07actual | — | 2026-08-19 |
| PFE | Pfizer | $155.3B | Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)NCT06353087observationalPercentage of Participants Achieving >= 75% Improvement From Baseline in Eczema Area and Severity Index (EASI-75) Response at Week 2, 12, 52 | — | Completed | — | Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Immune System Diseases, Janus Kinase Inhibitors | 41 | 2024-06-19 | 2026-06-22actual | — | 2026-08-18 |
| PFE | Pfizer | $155.3B | A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaNCT06807281Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation | Phase 3 | Recruiting | Drug: Abrocitinib | Atopic Dermatitis | 500 | 2025-12-02 | 2032-02-22 | in 2,012 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.NCT06899204observationalPercentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date | — | Recruiting | Drug: Abrocitinib | Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic | 150 | 2026-04-24 | 2027-02-15 | in 179 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaNCT07216027Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12 | Phase 2 | Recruiting | Drug: PF-08049820, Placebo | Atopic Dermatitis, Eczema, Atopic | 165 | 2025-11-20 | 2028-02-02 | in 531 d | 2026-08-17 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234NCT07453602Number and percentage of participants who experience an adverse event (AE) or serious adverse event (SAE) | Phase 1 | Recruiting | Biological: ARQ-234 · Drug: Placebo | Atopic Dermatitis (AD), Eczema | 125 | 2026-03-02 | Apr 2028 | ≤ 619 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World SettingNCT05139836observationalPercentage of Participants Achieving Disease Control Defined by Atopic Dermatitis Control Tool (ADCT) Total Score <7 Points | — | Active, not recruiting | — | Atopic Dermatitis | 634 | 2021-12-13 | Sep 2027 | ≤ 406 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in ChinaNCT06421740observationalNumber of participants with a dose change | — | Completed | — | Atopic Dermatitis | 1,000 | 2024-06-07 | 2026-05-25actual | — | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisNCT06718101Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 | Phase 2 | Active, not recruiting | Drug: Lutikizumab, Placebo | Atopic Dermatitis | 83 | 2024-12-19 | May 2027 | ≤ 284 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaNCT07765888Difference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placebo | Phase 3 | Not yet recruiting | Drug: Tilrekimig · Other: Placebo | Atopic Dermatitis | 375 | 2026-08-14 | 2028-02-29 | in 558 d | 2026-08-14 |
| SNY | Sanofi | — | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)NCT06181435EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24 | Phase 3 | Completed | Drug: Amlitelimab, Placebo | Dermatitis Atopic | 589 | 2023-12-21 | 2025-11-25actual | — | 2026-08-13 |
| SNY | Sanofi | — | A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab TreatmentNCT06192563observationalChildren and Adolescents: Percentage (%) change from baseline in Eczema Area and Severity Index (EASI) score | — | Recruiting | Drug: Dupilumab | Atopic Dermatitis | 230 | 2023-11-30 | 2028-03-31 | in 589 d | 2026-08-13 |
| SNY | Sanofi | — | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical CorticosteroidsNCT06224348EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24 | Phase 3 | Completed | Drug: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors | Dermatitis Atopic | 643 | 2024-01-18 | 2025-08-21actual | — | 2026-08-13 |
| OGN | Organon and Co | $3.6B | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisNCT07265479Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8 | Phase 3 | Active, not recruiting | Drug: Tapinarof cream, 1%, Vehicle Cream | Atopic Dermatitis | 187 | 2025-12-29 | Aug 2027 | ≤ 376 d | 2026-08-12 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of Barzolvolimab in Patients With Atopic DermatitisNCT06727552Percent change from Baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 | Phase 2 | Active, not recruiting | Biological: Barzolvolimab · Drug: Matching placebo | Atopic Dermatitis | 131 | 2024-12-18 | 2026-05-06actual | — | 2026-08-11 |
| SNY | Sanofi | — | A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboNCT06015308Percentage of participants with a positive tetanus response at Week 16 | Phase 2 | Completed | Drug: Amlitelimab, Placebo · Biological: Tdap vaccine, PPS vaccine | Dermatitis Atopic | 224 | 2023-10-06 | 2025-10-01actual | — | 2026-08-10 |
| SNY | Sanofi | — | Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)NCT03992417observationalBaseline Characteristics: Medical history | — | Active, not recruiting | Drug: Dupilumab SAR231893 (REGN668) | Dermatitis Atopic | 955 | 2019-06-11 | 2027-03-31 | in 223 d | 2026-08-06 |
| AMGN | Amgen | $229.9B | A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05724199results2026-08-06Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24 | Phase 3 | Completed | Drug: Rocatinlimab · Other: Placebo | Atopic Dermatitis | 746 | 2023-02-21 | 2024-09-15actual | — | 2026-08-06 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisNCT06461897Percentage of Participants Achieving a 75% Reduction from Baseline in Eczema Area and Severity Index 75 (EASI 75) Score (other than US) | Phase 3 | Recruiting | Drug: Upadacitinib, Dupilumab | Atopic Dermatitis | 675 | 2024-08-19 | Jul 2030 | ≤ 1,441 d | 2026-08-06 |
| SNY | Sanofi | — | This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic TreatmentNCT07290803observationalNumber of Participants Utilizing Atopic Dermatitis (AD) Treatment | — | Recruiting | — | Atopic Dermatitis | 1,000 | 2025-11-17 | 2034-01-30 | in 2,720 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisNCT03952559results2023-06-29Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement | Phase 3 | Completed | Drug: Baricitinib, Placebo, Topical corticosteroid | Atopic Dermatitis | 516 | 2019-05-24 | 2022-04-24actual | — | 2026-08-05 |
| NKTR | Nektar Therapeutics | $2.5B | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNCT07690371US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24 | Phase 3 | Recruiting | Drug: Rezpegaldesleukin, Placebo | Moderate-to-Severe Atopic Dermatitis | 510 | 2026-06-29 | May 2028 | ≤ 650 d | 2026-08-04 |
| NKTR | Nektar Therapeutics | $2.5B | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNCT06136741Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16 | Phase 2 | Active, not recruiting | Drug: Rezpegaldesleukin, Placebo | Moderate to Severe Atopic Dermatitis | 396 | 2023-11-15 | 2025-05-06actual | — | 2026-08-03 |
| ABBV | AbbVie | $457.5B | Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)NCT07741838observationalPercentage of Participants Achieving Minimal Disease Activity (MDA) | — | Not yet recruiting | — | Atopic Dermatitis | 900 | 2026-09-30 | Jul 2028 | ≤ 711 d | 2026-08-03 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisNCT05559359Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline | Phase 3 | Active, not recruiting | Drug: Lebrikizumab, Placebo, Topical Corticosteroid (TCS) | Atopic Dermatitis, Eczema | 377 | 2022-10-18 | 2026-01-14actual | — | 2026-07-30 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisNCT05735483Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs) | Phase 3 | Enrolling by invitation | Drug: Lebrikizumab, Placebo | Atopic Dermatitis, Eczema | 333 | 2023-03-09 | Dec 2027 | ≤ 498 d | 2026-07-30 |
| APGE | Apogee Therapeutics, Inc. | $8.2B | A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic DermatitisNCT07003425Number of Participants with Treatment Emergent Adverse Events | Phase 2 | Recruiting | Drug: APG777, APG777, APG777 | Atopic Dermatitis | 350 | 2025-05-14 | Dec 2029 | ≤ 1,229 d | 2026-07-29 |
| SNY | Sanofi | — | The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic DermatitisNCT07467564observationalProportion of Participants with Hospital Anxiety and Depression Scale Anxiety (HADS-A) Sub-scores of Less Than 8 | — | Recruiting | Drug: Dupilumab | Atopic Dermatitis | 184 | 2026-02-24 | 2027-05-24 | in 277 d | 2026-07-28 |
| AMGN | Amgen | $229.9B | A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05633355results2026-07-24Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs) | Phase 3 | Completed | Drug: Rocatinlimab | Atopic Dermatitis | 187 | 2023-01-30 | 2025-07-31actual | — | 2026-07-24 |
| AMGN | Amgen | $229.9B | A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)NCT05398445results2026-07-23Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24 | Phase 3 | Completed | Drug: Rocatinlimab, Placebo | Atopic Dermatitis | 769 | 2022-05-31 | 2024-11-28actual | — | 2026-07-23 |
| AMGN | Amgen | $229.9B | A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)NCT05899816results2026-07-23Percentage of Participants With a Positive Anti-tetanus Response at Week 24 | Phase 3 | Completed | Drug: Rocatinlimab, Placebo | Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | 221 | 2023-06-07 | 2024-08-26actual | — | 2026-07-23 |
| SNY | Sanofi | — | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisNCT06130566EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24 | Phase 3 | Completed | Drug: Amlitelimab, Placebo | Dermatitis Atopic | 601 | 2023-11-08 | 2025-07-23actual | — | 2026-07-22 |
| APGE | Apogee Therapeutics, Inc. | $8.2B | A Study Evaluating APG777 in Atopic DermatitisNCT06395948Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI) | Phase 2 | Active, not recruiting | Drug: APG777, Placebo | Atopic Dermatitis | 470 | 2024-04-29 | Nov 2026 | ≤ 102 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsNCT06564389Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD) | Phase 1 | Recruiting | Drug: PF-07832837 · Other: Placebo | Healthy Participants, Atopic Dermatitis | 119 | 2024-11-05 | 2027-06-02 | in 286 d | 2026-07-22 |
| ALM.MC | Almirall, S.A. | $2.2B | Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisNCT05990725results2026-07-17Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24 | Phase 3 | Completed | Biological: Lebrikizumab | Atopic Dermatitis, Eczema | 260 | 2023-11-20 | 2025-06-25actual | — | 2026-07-17 |
| NKTR | Nektar Therapeutics | $2.5B | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNCT07711418US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24 | Phase 3 | Recruiting | Drug: Rezpegaldesleukin, Placebo | Moderate-to-Severe Atopic Dermatitis | 510 | Aug 2026 | Jun 2028 | ≤ 680 d | 2026-07-17 |
| AMGN | Amgen | $229.9B | A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05882877Number of Participants With Treatment-emergent Adverse Events | Phase 3 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Rocatinlimab · Other: Placebo | Atopic Dermatitis | 2,621 | 2023-05-31 | 2026-07-01actual | — | 2026-07-16 |
| BIOG-B.ST | BioGaia AB | $1.2B | Efficacy and Tolerability of a Probiotic OintmentNCT07701447Primary Endpoint | Not applicable | Not yet recruiting | Other: Probiotic Ointment, Comparator product | Atopic Dermatitis | 92 | Aug 2026 | Nov 2028 | ≤ 833 d | 2026-07-15 |
| SNY | Sanofi | — | Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisNCT05018806results2026-07-13Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score | Phase 2 | Completed | Drug: Placebo, Rilzabrutinib | Atopic Dermatitis | 124 | 2021-09-09 | 2023-06-23actual | — | 2026-07-13 |
| SNY | Sanofi | — | A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisNCT06407934US and US reference countries: Proportion of participants who are responders AND maintained vIGA-AD ≤2 without experiencing relapse among participants who were responders at baseline of ESTUARY | Phase 3 | Active, not recruiting | Drug: Amlitelimab, Placebo | Dermatitis Atopic | 1,541 | 2024-05-08 | 2026-06-10actual | — | 2026-07-10 |
| PFE | Pfizer | $155.3B | A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.NCT05689151observationalProportion of patients with an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) (on a 5- point scale) and a reduction from baseline of ≥2 points | — | Recruiting | Drug: Abrocitinib | Atopic Dermatitis, Eczema | 183 | 2023-03-09 | 2027-12-31 | in 498 d | 2026-07-07 |
| SNY | Sanofi | — | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)NCT03849716observationalBiomarker identification: Demographics | — | Completed | Other: Blood sample, Cheek swab | Dermatitis Atopic | 266 | 2019-04-05 | 2026-04-20actual | — | 2026-07-06 |
| ABBV | AbbVie | $457.5B | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabNCT06389136Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) | Phase 3 | Recruiting | Drug: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose | Atopic Dermatitis | 200 | 2024-06-14 | Aug 2026 | ≤ 11 d | 2026-07-06 |
| SNY | Sanofi | — | Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsNCT05492578Percentage of participants who experienced treatment-emergent adverse event (TEAE) | Phase 2/3 | Enrolling by invitation | Drug: Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids | Dermatitis Atopic | 1,663 | 2022-08-22 | 2029-01-22 | in 886 d | 2026-07-02 |
| SNY | Sanofi | — | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorNCT06241118EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36 | Phase 3 | Recruiting | Drug: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus | Dermatitis Atopic | 636 | 2024-02-29 | 2027-09-30 | in 406 d | 2026-07-02 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015Change from baseline in Eczema Area and Severity Index (EASI) score | Phase 2 | Active, not recruiting | Drug: KT-621 · Other: Placebo | Atopic Dermatitis | 200 | 2025-11-24 | Jun 2027 | ≤ 314 d | 2026-06-30 |
| AMGN | Amgen | $229.9B | A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)NCT05651711results2026-06-26Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24 | Phase 3 | Completed | Drug: Rocatinlimab · Other: Placebo | Atopic Dermatitis | 726 | 2022-12-14 | 2024-06-05actual | — | 2026-06-26 |
| REGN | Regeneron Pharmaceuticals | $76.1B | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisNCT07527923Occurrence of Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: REGN20423 · Other: Placebo | Healthy Volunteer, Atopic Dermatitis | 144 | 2026-05-22 | 2028-06-23 | in 673 d | 2026-06-25 |
| ABBV | AbbVie | $457.5B | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)NCT03569293results2022-02-03Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 | Phase 3 | Completed | Drug: Placebo for Upadacitinib, Upadacitinib | Atopic Dermatitis | 912 | 2018-08-13 | 2021-01-06actual | — | 2026-06-17 |
| CSTL | Castle Biosciences Incorporated | $887M | Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis FlaresNCT07645820observationalRelationship between skin measurements and subsequent atopic dermatitis flares | — | Recruiting | Device: Nevisense electrical impedance spectroscopy | Atopic Dermatitis | 450 | 2026-05-29 | 2027-04-01 | in 224 d | 2026-06-12 |
| APGE | Apogee Therapeutics, Inc. | $8.2B | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisNCT07027527Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: APG777, APG990, Dupilumab | Atopic Dermatitis | 86 | 2025-06-04 | Dec 2026 | ≤ 133 d | 2026-06-08 |
| ABBV | AbbVie | $457.5B | Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic DermatitisNCT05959083observationalPercentage of Participants With Incidence of Serious Infections | — | Completed | — | Atopic Dermatitis (AD) | 200 | 2023-08-18 | 2026-05-07actual | — | 2026-06-04 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)NCT03607422results2022-03-28Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 | Phase 3 | Completed | Drug: Placebo for Upadacitinib, Upadacitinib | Atopic Dermatitis | 912 | 2018-07-27 | 2021-03-11actual | — | 2026-06-02 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)NCT02612454Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit | Phase 3 | Active, not recruiting | Drug: Dupilumab | Atopic Dermatitis | 880 | 2015-10-15 | 2026-10-07 | in 48 d | 2026-05-29 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema TrialNCT05590585results2026-01-02Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) | Phase 4 | Completed | Drug: dupilumab · Other: Topical emollient (moisturizer) | Moderate-to-Severe Atopic Dermatitis, Atopic Eczema | 124 | 2023-01-11 | 2024-11-14actual | — | 2026-05-27 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisNCT06238817results2026-05-22Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8 | Phase 3 | Completed | Drug: Ruxolitinib Cream, Vehicle Cream | Atopic Dermatitis | 241 | 2024-04-26 | 2025-05-21actual | — | 2026-05-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenNCT07006792Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from Baseline | Phase 4 | Active, not recruiting | Drug: Lebrikizumab | Atopic Dermatitis | 233 | 2025-06-16 | 2026-05-14actual | — | 2026-05-22 |
| SNY | Sanofi | — | French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)NCT06837454observationalPrevious and Current Treatments for Atopic Dermatitis (AD) | — | Recruiting | — | Atopic Dermatitis | 600 | 2025-02-04 | 2027-05-13 | in 266 d | 2026-05-20 |
| TTRX | Turn Therapeutics | $298M | A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)NCT07355075Change in Investigator Global Assessment (IGA) at Week 8 | Phase 2 | Recruiting | Combination product: GX-03 · Other: Vehicle | Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis | 110 | 2025-07-11 | 2026-07-10 | — | 2026-05-18 |
| SNY | Sanofi | — | Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic DermatitisNCT06099704observationalPercentage of participants achieving a reduction in Eczema Area and Severity Index (EASI) of at least 75% at 6 months | — | Completed | — | Moderate to Severe Atopic Dermatitis | 305 | 2023-10-10 | 2026-04-14actual | — | 2026-05-15 |
| ALM.MC | Almirall, S.A. | $2.2B | Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisNCT05916365Proportion of the Participants who will Discontinue from Study Treatment due to Treatment-emergent Adverse Events (TEAEs) | Phase 3 | Completed | Biological: Lebrikizumab | Atopic Dermatitis | 174 | 2023-05-23 | 2026-04-23actual | — | 2026-05-14 |
| PFE | Pfizer | $155.3B | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisNCT05995964The number of participants achieving ≥75% improvement in EAS175 from baseline at week16. | Phase 2 | Recruiting | Drug: PF-07275315, PF-07264660 · Other: Placebo | Atopic Dermatitis | 340 | 2023-08-22 | 2026-10-19 | in 60 d | 2026-05-04 |
| SNY | Sanofi | — | Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic DermatitisNCT05769777Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Active, not recruiting | Drug: Amlitelimab | Dermatitis Atopic | 999 | 2023-04-03 | 2031-06-11 | in 1,756 d | 2026-04-23 |
| SNY | Sanofi | — | An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 SubstratesNCT06686628AUC and AUClast for CYP substrates | Phase 1 | Completed | Drug: Amlitelimab, Midazolam, Caffeine, Metoprolol, Omeprazole, Warfarin | Dermatitis Atopic | 23 | 2024-11-20 | 2025-11-21actual | — | 2026-04-23 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisNCT06526182Part 1: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Score Less than or Equal to (<=) 7 at Week 24 | Phase 3 | Active, not recruiting | Biological: Lebrikizumab · Other: Placebo | Dermatitis, Atopic, Eczema | 520 | 2024-07-03 | 2027-04-25 | in 248 d | 2026-04-21 |
| SNY | Sanofi | — | A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisNCT06790121Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24 | Phase 2 | Completed | Drug: Lunsekimig, Placebo | Dermatitis Atopic | 150 | 2025-01-30 | 2026-02-12actual | — | 2026-04-21 |
| SNY | Sanofi | — | A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic DermatitisNCT05983068Percent change from baseline in TEWL after 5 STS assessed on lesional skin. | Phase 4 | Active, not recruiting | Drug: dupilumab | Dermatitis Atopic | 48 | 2024-02-22 | 2027-04-29 | in 252 d | 2026-04-13 |
| AMGN | Amgen | $229.9B | A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic DermatitisNCT06224192Proportion of Full-dose Self-administered Rocatinlimab Injections Among Total Attempted Injections up to Week 16 | Phase 3 | Completed | Combination product: Rocatinlimab Prefilled Syringe, Rocatinlimab AI | Atopic Dermatitis | 151 | 2024-04-02 | 2025-04-11actual | — | 2026-03-25 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706Percent Change in Eczema Area and Severity Index (EASI) | Phase 2 | Active, not recruiting | Drug: ATI-045, Placebo | Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema | 110 | 2025-05-30 | Aug 2026 | ≤ 11 d | 2026-03-25 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.NCT05387980observationalNumber of Participants with adverse drug reactions | — | Active, not recruiting | Drug: CIBINQO | Atopic Dermatitis | 1,128 | 2022-04-19 | 2028-11-01 | in 804 d | 2026-03-19 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe ADNCT06345404Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms | Phase 1 | Completed | Drug: Soquelitinib, Placebo | Atopic Dermatitis | 82 | 2024-04-16 | 2026-01-28actual | — | 2026-03-12 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisNCT06585202Incidence and severity of treatment emergent adverse events (TEAEs) | Phase 2 | Completed | Drug: ATI-2138 | Atopic Dermatitis | 14 | 2024-08-19 | 2025-03-13actual | — | 2026-03-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of ColorNCT05372419results2025-06-11Percentage of Participants Achieving Eczema Area and Severity Index 75 (≥75% Reduction From Baseline in EASI) at Week 16 | Phase 3 | Completed | Drug: Lebrikizumab | Atopic Dermatitis | 90 | 2023-01-12 | 2024-05-03actual | — | 2026-03-09 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADNCT07441395Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12 | Phase 2 | Recruiting | Drug: Soquelitinib, Placebo | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic | 200 | Feb 2026 | Jun 2027 | ≤ 314 d | 2026-03-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected PregnancyNCT04173442observationalRate of major structural defects | — | Completed | Drug: dupilumab | Atopic Dermatitis (AD), Asthma | 581 | 2018-10-24 | 2025-11-04actual | — | 2026-03-04 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)NCT05029895observationalPercentage of Participants with Serious Infection | — | Completed | — | Atopic Dermatitis | 167 | 2021-09-29 | 2025-09-17actual | — | 2026-02-27 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral UpadacitinibNCT05451316observationalPercentage of participants achieving Worst Pruritus Numerical Rating Scale (WP-NRS) reduction ≥ 4. | — | Completed | — | Atopic Dermatitis | 1 | 2022-12-08 | 2024-11-02actual | — | 2026-02-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabNCT05369403results2025-03-19Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16 | Phase 3 | Completed | Drug: Lebrikizumab | Atopic Dermatitis | 86 | 2022-12-19 | 2024-01-11actual | — | 2026-02-25 |
| SNY | Sanofi | — | Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in SpainNCT06415175observationalDemographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age | — | Active, not recruiting | Drug: Dupilumab | Atopic Dermatitis | 143 | 2024-11-14 | 2026-09-30 | in 41 d | 2026-02-25 |
| ABBV | AbbVie | $457.5B | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisNCT06701331Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75 | Phase 3 | Active, not recruiting | Drug: Placebo, Upadacitinib | Atopic Dermatitis | 99 | 2024-12-22 | Jan 2027 | ≤ 164 d | 2026-02-23 |
| ABBV | AbbVie | $457.5B | A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic ArthritisNCT04541810observationalPercentage of Participants With Adverse Events | — | Completed | — | Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | 2,369 | 2021-01-26 | 2025-12-31actual | — | 2026-02-12 |
| SNY | Sanofi | — | Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic DermatitisNCT06039241observationalNumber of patients who maintain Eczema Area and Severity Index (EASI) ≤ 7 OR peak pruritus Numerical Rating Scale (NRS) ≤ 4 OR Dermatology Life Quality Index (DLQI) ≤ 5 | — | Recruiting | — | Atopic Dermatitis | 900 | 2023-03-07 | 2028-03-08 | in 566 d | 2026-02-12 |
| ABBV | AbbVie | $457.5B | Expanded Access to UpadacitinibNCT04159597expanded access | — | Available | Drug: Upadacitinib | Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis | — | — | — | — | 2026-01-30 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)NCT06945458Incidence of adverse events (AEs) | Phase 1 | Completed | Drug: KT-621 | Atopic Dermatitis | 22 | 2025-04-17 | 2025-11-10actual | — | 2026-01-26 |
| AMGN | Amgen | $229.9B | A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy ParticipantsNCT06438263Maximum Plasma Concentration (Cmax) of Rocatinlimab | Phase 1 | Completed | Drug: Rocatinlimab, Rocatinlimab | Atopic Dermatitis | 231 | 2024-08-06 | 2025-05-03actual | — | 2026-01-20 |
| AMGN | Amgen | $229.9B | A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05704738Achievement of a Validated Investigator's Global Assessment for Atopic Dermatitis Score of 0 (Clear) or 1 (Almost Clear) with a ≥ 2 Point Reduction From Baseline (vIGA-AD 0/1) at Week 24 | Phase 3 | Completed | Drug: Rocatinlimab, Placebo | Atopic Dermatitis | 532 | 2023-04-20 | 2025-02-27actual | — | 2026-01-16 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis ParticipantsNCT06934980observationalVolume of dISF collected from normal skin in healthy participants and lesional skin from AD patients | — | Completed | Device: Microneedle Device | Atopic Dermatitis, Healthy Volunteers | 20 | 2025-06-27 | 2025-12-19actual | — | 2026-01-16 |
| PFE | Pfizer | $155.3B | Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisNCT03422822Treatment emergent adverse events | Phase 3 | Completed | Drug: Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo, Abrocitinib 100 mg, Abrocitinib 100 mg, Abrocitinib 200 mg | Dermatitis, Atopic | 3,166 | 2018-03-08 | 2025-12-22actual | — | 2026-01-15 |
| AMGN | Amgen | $229.9B | A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese ParticipantsNCT06214481Maximum Observed Plasma Concentration (Cmax) of Rocatinlimab | Phase 1 | Completed | Drug: Rocatinlimab | Atopic Dermatitis | 20 | 2024-01-23 | 2024-05-27actual | — | 2026-01-07 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)NCT03428646observationalRegistry Assessment: Baseline Characteristics | — | Active, not recruiting | Drug: Dupilumab | Dermatitis, Atopic | 858 | 2018-04-06 | 2027-03-30 | in 222 d | 2025-12-29 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisNCT03568318results2022-03-31Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 | Phase 3 | Active, not recruiting | Drug: Placebo, Upadacitinib, Topical corticosteroids (TCS) | Atopic Dermatitis | 1,533 | 2018-08-09 | 2021-02-16actual | — | 2025-12-23 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisNCT04804605results2025-12-23Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) | Phase 3 | Completed | Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Atopic Dermatitis Eczema | 1,220 | 2021-02-25 | 2024-05-28actual | — | 2025-12-23 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)NCT04845620results2025-12-23Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 | Phase 3 | Completed | Drug: Roflumilast Cream 0.05%, Vehicle Cream | Atopic Dermatitis Eczema | 652 | 2021-04-07 | 2023-06-01actual | — | 2025-12-23 |
| AMGN | Amgen | $229.9B | Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic DermatitisNCT05891119Maximum Observed Serum Concentration (Cmax) of CYP450 Substrate | Early Phase 1 | Completed | Dietary supplement: Caffeine, Vitamin K · Drug: Metoprolol, Midazolam, Warfarin, Omeprazole, Rocatinlimab | Atopic Dermatitis | 21 | 2023-06-03 | 2024-08-28actual | — | 2025-12-23 |
| AMGN | Amgen | $229.9B | A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsNCT06268860Maximum Observed Serum Concentration (Cmax) of Rocatinlimab | Phase 1 | Completed | Drug: Rocatinlimab vial injection · Combination product: Rocatinlimab prefilled syringe | Atopic Dermatitis | 240 | 2024-02-15 | 2024-08-30actual | — | 2025-12-23 |
| INCY | Incyte Corporation | $24.7B | The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.NCT05696392results2025-12-19Change From Baseline in Total Sleep Time (TST) as Measured by Ōura Ring Wearable Device at Week 8 | Phase 4 | Terminatedsponsor's stated reason: The study was terminated due to lack of enrollment. | Drug: ruxolitinib cream | Atopic Dermatitis | 47 | 2023-03-16 | 2025-01-22actual | — | 2025-12-19 |
| SNY | Sanofi | — | Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisNCT06058156Percent change from baseline in EASI | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: SAR444656 (KT-474), Placebo | Atopic Dermatitis | 70 | 2023-11-09 | 2025-10-23actual | — | 2025-12-11 |
| INCY | Incyte Corporation | $24.7B | Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationNCT06259669observationalNumber of major congenital malformation (MCM)s | — | Recruiting | Drug: Ruxolitinib Cream | Pregnancy Related, Atopic Dermatitis | 958 | 2023-09-13 | 2032-08-01 | in 2,173 d | 2025-12-11 |
| INCY | Incyte Corporation | $24.7B | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisNCT06627335observationalNumber of major congenital malformation (MCM)s | — | Recruiting | Drug: Ruxolitinib Cream, TCS | Pregnancy Related, Atopic Dermatitis | 5,621 | 2023-03-27 | 2027-08-15 | in 360 d | 2025-12-11 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisNCT06998056Subject incidence of adverse events | Phase 2 | Completed | Drug: ARQ-151 cream 0.05% | Atopic Dermatitis (Eczema) | 101 | 2025-06-09 | 2025-12-04actual | — | 2025-12-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Atopic Dermatitis is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Atopic Dermatitis
- Dermatitis, Atopic
- Dermatitis Atopic
- Atopic Dermatitis (AD)
- Atopic Dermatitis Eczema
- Moderate-to-Severe Atopic Dermatitis
- Atopic Eczema
- Atopic Dermatitis (Eczema)
- Atopic Dermatitis, Unspecified
- Eczema Atopic Dermatitis
- Moderate to Severe Atopic Dermatitis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Atopic Dermatitis” (a text search, wider than this page)